Endothelin Antagonist Trial in Mildly Symptomatic Pulmonary Arterial Hypertension Patients - EARLY


The goal of this trial was to assess the efficacy of bosentan in patients with mildly symptomatic pulmonary arterial hypertension (PAH) (World Health Organization [WHO] functional class [FC] II). Most clinical trials on the use of these agents have been conducted primarily in patients with WHO FC III and IV symptoms.